[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"polypharmacy-patients\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:polypharmacy-patients":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100574960","ipgx-pilot-whole-genome-sequencing-extension-cohort-100574960",false,"NCT06766071","IPGx PILOT Whole Genome Sequencing Extension Cohort","The Texas A&M Interprofessional Pharmacogenomics PILOT Whole Genome Sequencing (WGS) Cohort","Inclusion Criteria:\n\n* Individuals taking 5 or more medications, including over the counter drugs, supplements, natural products, cannabis produces, or other recreational drugs.\n* Ability to give and comprehend the consent process.\n* Consent to donate urine samples, genetic data through buccal swabs and blood samples, and undergo a comprehensive history and physical examination.\n* All genders\n* Age 18-100\n\nExclusion Criteria:\n\n* Subject has been diagnosed or is being treated for any cancer other than basal cell cancer in the last 5 years. Patients with metastatic melanoma in the last 5 years will be excluded.\n* Admitted to hospice.\n* Patient has ever been diagnosed with Hepatitis B or C.\n* Patient has ever been diagnosed with active liver disease, hepatomegaly, grossly abnormal liver function. Meld score \\>10, ALT, or AST \\>100U\u002FL or an AST\u002FALT ratio \\>2\n* Patients taking imidazole antifungal medication.\n* Declines to participate or interact with staff\u002Fshare their medical status.\n* A diagnosis of Alzheimer's disease or related dementias in a medical record indicates a progressive, debilitating condition that impairs memory, thought processes, and functioning.\n* Pregnant patients will be excluded.\n* Individuals who are unable or unwilling to provide consent will be excluded.\n* Unable to verbally communicate and comprehend English language.","ALL","18 Years","100 Years",{"count":20,"type":21},50,"ESTIMATED","180 Days","OBSERVATIONAL","The investigator's primary aim is to evaluate polypharmacy-associated adverse drug reactions (ADR) in a pilot study of at-risk patients using state-of-the-art pharmacogenomic technology and to use this information to make recommendations for optimization of pharmacotherapy regimens. The data from the pilot cohort will be used to optimize and integrate a customized electronic decision support (clinical semantic network; CSN) dashboard to identify drug regimens that should be modified, replaced, or discontinued. A secondary objective of the pilot study is to evaluate the capacity\u002Fsaturation of CYP P450 enzymatic pathways in polypharmacy patients. A third objective is to determine the feasibility of the planned informatics workflows between the CLIA lab, the EMR, and the Family Medicine Practice including Whole Genome Sequencing (WGS).",[26,27],"Adverse Drug Reaction (ADR)","Polypharmacy Patients",[29],"whole genome sequencing","RECRUITING","2025-01-03",{"date":33,"type":34},"2025-01-09","ACTUAL",{"date":36,"type":21},"2025-01",{"date":38,"type":21},"2026-01",{"name":40,"class":41},"Texas A&M University","OTHER"]